

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Health Group Limited**  
**中國衛生集團有限公司**

*(Carrying on business in Hong Kong as CHG HS Limited)*

*(Incorporated in Bermuda with limited liability)*

*(Stock Code: 673)*

**CANCELLATION OF SHARE OPTIONS**

Reference is made to the announcement (the “**Announcement**”) of China Health Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 February 2026 in relation to the grant of 40,638,000 Options under the Scheme to 11 Grantees. Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

The Board announces that on 13 February 2026, pursuant to the terms of the Scheme, the Board exercised its discretion to cancel in full the 40,638,000 Options granted on 2 February 2026, which had not been validly exercised by any Grantee, by giving notice in writing to the Grantees stating that such Options are thereby cancelled.

**Number of Shares Available for Future Grants**

As the Options cancelled will be regarded as utilised for the purpose of calculating the Scheme Mandate Limit and the Service Provider Limit under the Scheme, the number of Shares available for future grants under the Scheme Mandate Limit and the Service Provider Sublimit of the Scheme remain to be 7,261,476 and 4,789,947 respectively.

By order of the Board  
**China Health Group Limited**  
**Cao Xu**

*Chairman of the Board and Executive Director*

Hong Kong, 13 February 2026

*As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Cao Xu (Chairman), Mr. Chung Ho and Ms. Ying Rensi; two non-executive Directors, namely, Mr. Ying Wei, and Mr. Huang Lianhai; and three independent non-executive Directors, namely, Mr. Li Hongyi, Mr. Wu Hui and Mr. Yang Huimin.*